Abstracts tagged "skin"

Abstract Number: 0972 • ACR Convergence 2025
Prominent endothelial senescence in systemic sclerosis skin
Poulami Dey¹, William D Brodie², Megan N Mattichak³, Alexander Cai³, Qi Wu⁴, Johann Gudjonsson⁵, Dinesh Khanna⁵, John Varga⁵ and Pei-Suen Tsou⁵, ¹Michigan Medicine, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁴Michigan Medicine, Ann Arbor, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by extensive damage of the microvessels in multiple organs. We and others showed that endothelial cells (ECs) isolated from…
Abstract Number: 0244 • ACR Convergence 2025
Effectiveness and safety of Anifrolumab in Non-Systemic Cutaneous Lupus
Carmen Lasa Teja¹, Javier Loricera², Marcos López-Hoyos³, Carmen Bejerano-Herreria⁴, Andrea Estébanez⁵, Mireia Sanmartin Martínez⁶, Marta González-Fernández⁷, Ivan Ferraz Amaro⁸ and Ricardo Blanco⁹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁵Department of Dermatology, Hospital Universitario Doctor Peset, Valencia, Spain, Valencia, Spain, ⁶Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁷Basurto University Hospital, Bilbao, Pais Vasco, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Anifrolumab is a human monoclonal antibody targeting the type I interferon receptor, approved for the treatment of systemic lupus erythematosus (SLE), with demonstrated efficacy…
Abstract Number: 2503 • ACR Convergence 2025
Validation of a Composite Biomarker Score To Predict Modified Rodnan Skin Score: Insight From Autologous Stem Cell Transplantation International Scleroderma trial
stefano rodolfi¹, kristina clark², bahja Ahmed Abdi¹, medha kanitkar³, Voon H. Ong³, Alexandre Voskuijl⁴, Jeska de Vries-Bouwstra⁵, Jacob M. van Laar⁶, Christopher Denton⁷ and julia Spierings⁸, ¹University College London, London, United Kingdom, ²Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶UMC Utrecht, Utrecht, Netherlands, ⁷University College London, UK, London, United Kingdom, ⁸Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands
Background/Purpose: Skin fibrosis is a cardinal manifestation of diffuse cutaneous systemic sclerosis (dcSSc) and is routinely measured via the modified Rodnan skin score (mRSS); however,…
Abstract Number: 0967 • ACR Convergence 2025
Single-Cell RNA Sequencing Reveals a Prominent Pro-Inflammatory Gene Signature of Dermal Fibroblasts in Pre-Stages of SSc
Lumeng Li¹, Elena Pachera², Rucsandra Dobrota³, Sinziana Muraru⁴, Kristina Bürki³, Carina Mihai⁵, Muriel Elhai⁶, Laura Much⁷, Astrid Hofman³, Pietro Bearzi¹, Anna-Maria Hoffmann-Vold⁸ and Oliver Distler⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁴University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁵University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁶University Hospital zurich, Zürich, Switzerland, ⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Oslo University Hospital, Oslo, Norway, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The poor prognosis of SSc patients demands an urgent need to prevent disease onset. Recently, we reported a global pro-inflammatory gene signature of dermal…
Abstract Number: 0223 • ACR Convergence 2025
Timely Dermatologic Diagnosis and Management Changes in Systemic Collagen Vascular Diseases: Experiences from the Rheumatology-Dermatology Combined Clinic
Gopisree Peringeth¹, Benedict Wu¹, Shudan Wang², Beth McLellan³, Clement Tagoe⁴ and Jeanie Lee¹, ¹Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, NY, ²Montefiore Medical Center, Bronx, NY, ³Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, ⁴Albert Einstein College of Medicine, FRESH MEADOWS, NY
Background/Purpose: Collagen vascular diseases (CVD) often present with skin manifestations, but it is not always clear whether these changes are directly related to the underlying…
Abstract Number: 2498 • ACR Convergence 2025
Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease
Poulami Dey¹, Rachael Bogle², Qinmengge Li³, Olesya Plazyo⁴, Rosemary Gedert⁴, Carleigh Zahn⁴, Pei-Suen Tsou⁴, John Varga⁴, Lam Tsoi⁴, Johann Gudjonsson⁴ and Dinesh Khanna⁴, ¹Michigan Medicine, Ann Arbor, MI, ²University of Michigan, Holland, OH, ³University of Michigan, Ypsilanti, MI, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin fibrosis, dysregulated immune response, and vascular system dysfunction. Interstitial lung disease (ILD) is one of the leading…
Abstract Number: 0964 • ACR Convergence 2025
A Single-Cell Atlas Reveals Dermal Endothelial Heterogeneity and Disease-Specific Pathways in Autoimmune Disorders
Haoyu Pan¹, Jinyi Qian¹, Shuyi Yu¹, Zhixia Yang¹, Jason S. Knight², Eliza Tsou³ and Hui Shi⁴, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan; Ann Arbor, Michigan, USA., Ann Arbor, MI, ⁴Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: Autoimmune conditions with skin involvement, including scleroderma (SSc), antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and psoriasis (PSO), involve intricate interactions between immune cells…
Abstract Number: 0118 • ACR Convergence 2025
Single-cell RNA sequencing of skin reveals vascular dysregulation in antiphospholipid syndrome
Ecem Sevim¹, Sumith Panicker², Gustaf Wigerblad³, Stefania Dell'orso⁴, Sharon Osgood², Leslie Castelo-Soccio⁵, Keisuke Nagao⁶ and Yogendra Kanthi⁷, ¹NIAMS/NIH, Bethesda, MD, ²NHLBI/NIH, Bethesda, ³National Institutes of Health, Stockholm, Sweden, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵NIAMS/NIH, Bethesda, ⁶NIAMS, Bethesda, MD, ⁷National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune thromboinflammatory disorder defined by persistent antiphospholipid antibodies (aPL) and characterized clinically by macrovascular thrombosis, microvascular disease, and…
Abstract Number: 2495 • ACR Convergence 2025
IL-6/STAT3 Signaling is Central for Chemokine Production in E2-Induced Dermal Inflammation
Nicolas Ancona¹, Yucui Li², Ludivine Renaud³, Carol Feghali-Bostwick³ and DeAnna Baker Frost³, ¹MUSC Rheumatology & Immunology, Charleston, SC, ²Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi, Medical University Taiyuan, Shanxi, China (People's Republic), ³Medical University of South Carolina, Charleston, SC
Background/Purpose: Scleroderma (SSc) is an autoimmune disease characterized by dermal inflammation and fibrosis. Patients with SSc have high systemic levels of estradiol (E2), a form…
Abstract Number: 0962 • ACR Convergence 2025
Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Dennis Bleck¹, Karen Drechsel², Tim Filla³, Yi-Nan Li⁴, Andrea-Hermina Györfi⁵, Alexandru-Emil Matei⁶ and Jörg Distler⁷, ¹University Hospital Düsseldorf, Department of Rheumatology, Hiller Research Center, Düsseldorf, Nordrhein-Westfalen, Germany, ²University Hospital Düsseldorf, Department of Rheumatology, Hiller Research center, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁶Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease and presents a significant medical challenge. It is characterized by fibrotic tissue remodeling, along…
Abstract Number: 2418 • ACR Convergence 2025
ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin
Mehrnaz Gharaee-Kermani¹, Svenja Henning², John LaCava³, Tomas Mustelin⁴ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Groningen, Groningen, Groningen, Netherlands, ³Rockefeller University, New York City, NY, NJ, ⁴University of Washington, Seattle, WA
Background/Purpose: Type I interferons (IFNs) are elevated in the skin and blood of patients with systemic (SLE) and cutaneous (CLE) lupus erythematosus. Upregulation of type…
Abstract Number: 0949 • ACR Convergence 2025
The Cancer-associated Female-biased Factor VGLL3 Drives Autoimmunity and Fibrosis
Mehrnaz Gharaee-Kermani¹, Poulami Dey², Vincent van Drongelen¹, Joanna Rew¹, Rachael Bogle³, Marisa Hildebrandt¹, Benjamin Klein¹, Rezvan Moallemian¹, Monique E Verhaegen¹, Andrzej A Dlugosz⁴, Lam Tsoi¹, J. Michelle Kahlenberg¹, Johann Gudjonsson¹ and Allison C Billi¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, Ann Arbor, MI, ³University of Michigan, Holland, OH, ⁴University of Michigan, Ann Arbor
Background/Purpose: Autoimmune disease is far more common in women than men. We have determined that the skin of healthy women is primed for autoimmunity due…
Abstract Number: 2374 • ACR Convergence 2025
Bimekizumab Efficacy And Safety Through 5 Years In Patients With Moderate To Severe Plaque Psoriasis In The US And Canada
Andrew Blauvelt¹, Saakshi Khattri², Phoebe Rich³, Ronald Vender⁴, Kenneth B. Gordon⁵, Balint Szilagyi⁶, Heather Herr⁷, Bertram Knapp⁶, Delphine Deherder⁸, Sarah Kavanagh⁹ and Kim Papp¹⁰, ¹Blauvelt Consulting, LLC, Portland, OR, ²The Mount Sinai Hospital, New York, NY, ³Oregon Dermatology and Research Center, Portland, OR, ⁴Dermatrials Research Inc., Hamilton, ON, Canada, ⁵Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, ⁶UCB, Monheim am Rhein, Germany, ⁷UCB, Smyrna, GA, ⁸UCB, Braine-l'Alleud, Belgium, ⁹UCB, Morrisville, NC, ¹⁰Probity Medical Research and Alliance Clinical Trials, Waterloo, and Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Given the chronic nature of psoriasis, and the loss of response observed with biologic therapies over time, it is crucial to establish the long-term…
Abstract Number: 0927 • ACR Convergence 2025
Improved Skin Lymphatic Flow Regulates Dendritic Cells to Mediate Lymph Node Fibroblast Alterations and Immune Responses in Lupus
Mir Howlader¹ and Theresa Lu², ¹Weill Cornell Medical College, Brooklyn, NY, ²Hospital for Special Surgery, NEW YORK, NY
Background/Purpose: Lupus is a chronic autoimmune disease with a global loss of self-tolerance. Lupus patients are photosensitive where exposure to even ambient sunlight results in…
Abstract Number: 2175 • ACR Convergence 2025
Skin Manifestations of Rheumatic Diseases: Educating Providers to Improve Diagnostic Skills
Brittany Ashe¹, Ellen Koch², Tiffany Yang¹ and Kathryn Torok², ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Among pediatric patients with scleroderma, there is a significant delay between onset of symptoms and diagnosis ranging from 1.2-1.6 years for Localized Scleroderma (LS)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].